Brad Lipson
Family Medicine · Royal Palm Beach, FLNPI 1508930447
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,614 of the $16,986 with a category attached, or 68.4%. It is spread thinly across 34 manufacturers, the largest accounting for just 20.0%. Reporting peaked in 2024 at $3,401 and has fallen 66.1% since, to $1,153 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 486 payments — averaging $34.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3K
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$1K
- Novartis$1K
- Genentech USA, Inc.$983
- plus $6K from 28 others
Across 46 payments — averaging $104,770 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4.7M
- AstraZeneca$111K
- Merck$19K
- Indivior Inc.$125
What the payments were for
- Consulting fees$6804%
- Travel & lodging$4,27225%
- Food & beverage$11,61468%
- Education$4202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 33 | $3,401 |
| AbbVie(2 entities) | 85 | $2,137 |
| Novo Nordisk | 65 | $1,495 |
| AstraZeneca | 60 | $1,371 |
| Novartis | 9 | $1,214 |
| Genentech USA, Inc. | 6 | $983 |
| Novo Nordisk AS | 1 | $680 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $676 |
| Lilly USA, LLC | 34 | $645 |
| Amarin Pharma, Inc. | 25 | $576 |
| Amgen(2 entities) | 17 | $437 |
| Biohaven Pharmaceuticals, Inc. | 12 | $435 |
| Johnson & Johnson | 9 | $411 |
| Ascensia Diabetes Care US Inc. | 1 | $398 |
| Boehringer Ingelheim | 9 | $313 |
| Bausch Health US, LLC | 17 | $291 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $256 |
| Pfizer | 9 | $160 |
| Teva Pharmaceuticals USA, Inc. | 3 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $135 |
| Merck | 7 | $126 |
| Abbott | 5 | $90 |
| Orexo US, Inc. | 5 | $89 |
| Eisai Inc. | 5 | $81 |
| GSK | 3 | $78 |
| Bayer | 3 | $76 |
| Adlon Therapeutics L.p. | 5 | $68 |
| Gilead | 4 | $66 |
| Indivior Inc. | 2 | $47 |
| Biogen | 1 | $24 |
| Alkermes, Inc. | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,986 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Royal Palm Beach
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.